Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of the EMPYREAN study.
Motoki H, Masuda I, Yasuno S, Oba K, Shoin W, Usami S, Saito Y, Waki M, Komatsu M, Ueshima K, Nakagawa Y, Son C, Yonemitsu S, Hiramitsu S, Konda M, Onishi K, Kuwahara K. Motoki H, et al. Among authors: hiramitsu s. ESC Heart Fail. 2020 Oct;7(5):3134-3141. doi: 10.1002/ehf2.12825. Epub 2020 Jun 23. ESC Heart Fail. 2020. PMID: 32578353 Free PMC article. Clinical Trial.
Determination of the B-type natriuretic peptide level as a criterion for abnormalities in Japanese individuals in routine clinical practice: the J-ABS Multi-Center Study (Japan Abnormal BNP Standard).
Kawai M, Yoshimura M, Harada M, Mizuno Y, Hiramitsu S, Shimizu M, Shoda T, Kuwahara K, Miyagishima K, Ueshima K, Nakao K. Kawai M, et al. Among authors: hiramitsu s. Intern Med. 2013;52(2):171-7. doi: 10.2169/internalmedicine.52.8704. Epub 2013 Jan 15. Intern Med. 2013. PMID: 23318845 Free article.
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai N, Tokutake E, Uchiyama K, Sugawara M, Kakuda H, Wakasa Y, Mori H, Hisatome I, Waki M, Ohya Y, Kimura K, Saito Y; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kojima S, et al. Among authors: hiramitsu s. J Cardiol. 2017 Jan;69(1):169-175. doi: 10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20. J Cardiol. 2017. PMID: 27005768 Free article. Clinical Trial.
Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial.
Takahama H, Asakura M, Abe Y, Ajioka M, Aonuma K, Anzai T, Hayashi T, Hiramitsu S, Kawai H, Kioka H, Kimura K, Lim YJ, Matsuoka K, Motoki H, Nagata Y, Nakamura S, Ohte N, Ozaki Y, Sasaoka T, Tamaki S, Hamasaki T, Kitakaze M; J-TASTE investigators. Takahama H, et al. Among authors: hiramitsu s. Cardiovasc Drugs Ther. 2018 Aug;32(4):381-388. doi: 10.1007/s10557-018-6799-5. Cardiovasc Drugs Ther. 2018. PMID: 29974299
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Kojima S, et al. Among authors: hiramitsu s. Eur Heart J. 2019 Jun 7;40(22):1778-1786. doi: 10.1093/eurheartj/ehz119. Eur Heart J. 2019. PMID: 30844048 Free PMC article. Clinical Trial.
Rationale and Design of the CANONICAL Study　- Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus.
Kasama S, Masuyama T, Uemura S, Sato Y, Hiramitsu S, Masuda I, Yamamoto K, Komatsu S, Anzai T, Nishimura K, Ueda T, Kasahara M, Tanaka H, Susuta Y, Saito Y. Kasama S, et al. Among authors: hiramitsu s. Circ Rep. 2019 Aug 3;1(8):347-351. doi: 10.1253/circrep.CR-19-0049. Circ Rep. 2019. PMID: 33693161 Free PMC article.
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kojima S, et al. Among authors: hiramitsu s. Rheumatology (Oxford). 2022 May 30;61(6):2346-2359. doi: 10.1093/rheumatology/keab739. Rheumatology (Oxford). 2022. PMID: 34605897 Clinical Trial.
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Konishi M, et al. Among authors: hiramitsu s. Int J Cardiol. 2022 Feb 15;349:127-133. doi: 10.1016/j.ijcard.2021.11.076. Epub 2021 Dec 3. Int J Cardiol. 2022. PMID: 34864084 Clinical Trial.
New Conversion Formula Between B-Type Natriuretic Peptide and N-Terminal-Pro-B-Type Natriuretic Peptide　- Analysis From a Multicenter Study.
Ishihara S, Hiramitsu S, Kanaoka K, Taki M, Nakagawa H, Ueda T, Seno A, Nishida T, Onoue K, Soeda T, Ohtani T, Watanabe M, Kawakami R, Sakata Y, Kario K, Saito Y. Ishihara S, et al. Among authors: hiramitsu s. Circ J. 2022 Nov 25;86(12):2010-2018. doi: 10.1253/circj.CJ-22-0032. Epub 2022 May 25. Circ J. 2022. PMID: 35613887 Free article.
117 results